All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Arcutis' ZORYVE roflumilast cream for atopic dermatitis in children ages 2-5
Small molecule, autoimmune, PDE4 inhibitor, atopic dermatitis, pediatric population, topical therapy - Read more

THE GOOD
Business Development & Partnerships

Chiesi, Arbor forge $2.1B rare disease gene editing partnership targeting primary hyperoxaluria
Research collaboration, rare disease, gene therapy, milestone payments, global - Read more

Hikma, Celltrion expand MENA biosimilar alliance with six exclusive licensing agreements
Licensing deal, biosimilars, oncology, MENA region, commercialization - Read more

AstraZeneca, Algen partner on AI-driven immunology target discovery, $555M total consideration
Research collaboration, AI/ML, immunology, milestone payments - Read more

RedHill Biopharma licenses Talicia H. pylori treatment to Middle East partner for $1.8M plus royalties
Licensing deal, infectious disease, small molecule, Middle East, milestone payments, royalties - Read more

Ignota Labs, Kronos Bio acquire shelved clinical pipeline including CDK9, SYK inhibitors for under $300K
Acquisition, oncology, small molecule, drug discovery, milestone payments - Read more

Harness, Ono Venture launch MISBA Duo platform collaboration for rare triplet repeat disorders
Research collaboration, neurological, rare disease, antisense oligonucleotide, equity investment - Read more

Panacea Biotec secures $35.65M UNICEF supply deal for oral polio vaccines through 2030
Manufacturing agreement, vaccine, global, supply contract - Read more

Rentschler Biopharma expands Japan, South Korea CDMO services, partners with Summit Pharmaceuticals International
Manufacturing agreement, biologics, Asia, CDMO services - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

AstraZeneca, Daiichi Sankyo's Datroway shows survival benefit vs chemotherapy in Ph3 triple-negative breast cancer trial targeting TROP2
Antibody-drug conjugate, cancer, triple-negative breast cancer, TROP2 target, metastatic disease - Read more

AbbVie's botox hits Ph2 primary endpoint for upper limb essential tremor, targeting neurotoxin pathway
Protein therapy, neurological, botulinum toxin, essential tremor, movement disorders - Read more

Biomea Fusion reports positive Ph2 results for icovamenib targeting menin in type 2 diabetes at 52 weeks
Small molecule, metabolic, type 2 diabetes, kinase inhibitor, insulin deficiency - Read more

Abivax reports positive Ph3 ABTECT results for obefazimod in moderate-to-severe ulcerative colitis with updated safety
Small molecule, autoimmune, ulcerative colitis, oral therapy, JAK inhibitor - Read more

THE GOOD
Fundraises

TCG Crossover raises $1.3B third fund, life sciences investment firm backing biotech
Investment firm, life sciences, biotech funding - Read more

Trogenix raises $95M Series A, 'Trojan Horse' cancer therapies targeting solid tumors
Oncology, gene therapy, platform technology, clinical-stage - Read more

NanoPhoria raises $98M Series A for inhaled heart failure therapy NP-MP1
Cardiovascular, peptide therapy, nanoparticle delivery, preclinical - Read more

BioRestorative raises $1.1M registered direct offering, stem cell-based therapies development
Stem cell therapy, cell therapy, clinical-stage, metabolic disease - Read more

THE GOOD
Investments

Eli Lilly invests $1B-plus in India contract manufacturing partnerships for key drug supply
Multiple modalities, multiple disease areas, strategic, major transaction, operational - Read more

Mytos launches automated CDMO offering for stem cell therapies, targeting 2026 clinical readiness
Cell therapy, regenerative medicine, strategic, operational - Read more

THE GOOD
Marketing

Myeloid Therapeutics rebrands as Create Medicines, expands beyond myeloid cells to multi-immune programming
in vivo CAR therapy, oncology, strategic, operational - Read more

THE GOOD
Product Launches

Amgen launches DTC platform offering Repatha at 60% discount, lowest G7 price supporting Trump initiative
Monoclonal antibody, cardiovascular, strategic, cost reduction, competitive - Read more

THE GOOD
Regulatory

FDA lifts clinical hold on Neurizon's ALS drug NUZ-001, clearing path for human trials
Small molecule, neurological, regulatory, strategic - Read more

CDC adopts new chickenpox, COVID-19 vaccine guidelines separating MMRV shots, enabling individual-based decisions
Vaccine, infectious disease, regulatory, operational - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Skye Bioscience nimacimab targeting CB1 cannabinoid receptor fails Ph2 monotherapy trial for obesity treatment
Antibody, metabolic, monoclonal antibody, obesity, CB1 receptor, combination therapy - Read more

THE BAD
Earnings & Finances

AbbVie warns of $2.7B R&D hit, cuts full-year earnings forecast by $1.50 per share
Trispecific antibody, oncology, financial, major transaction - Read more

THE BAD
Lawsuits

Biogen ordered to pay Genentech $124M in royalties for Tysabri patent dispute
Monoclonal antibody, neurological, financial, regulatory, major transaction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here